Expert Analysis: ASCO GU 2023

CME

CCO Independent Conference Highlights of the 2023 ASCO Genitourinary Cancers Symposium

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: April 28, 2023

Expiration: April 27, 2024

Daniel P. Petrylak
Daniel P. Petrylak, MD
Elizabeth R. Plimack
Elizabeth R. Plimack, MD, MS, FASCO

Activity

Progress
1
Course Completed

References

  1. Robinson D, Van Allen EM, Wu YM, et al. Integrative clinical genomics of advanced prostate cancer. Cell2015;161:1215-1228.
  2. Rao A, Moka N, Hamstra DA, Ryan CJ. Co-Inhibition of androgen receptor and PARP as a novel treatment paradigm in prostate cancer-Where are we now? Cancers (Basel)2022;14.
  3. Li L, Karanika S, Yang G, et al. Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer. Sci Signal2017;10.
  4. Asim M, Tarish F, Zecchini HI, et al. Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer. Nat Commun2017;8:374.
  5. Agarwal N, Azad A, Carles J, et al. TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) Presented at: 2023 American Society for Clinical Oncology Genitourinary Cancers Symposium; February 16-18, 2023. Abstract LBA17.
  6. Clarke NW, Armstrong AJ, Thiery-Vuillemin A, et al. Abiraterone and olaparib for metastatic castration-resistant prostate cancer. NEJM Evid2022;1(9).
  7. Clarke NW, Armstrong AJ, Thiery-Vuillemin A, et al. Final overall survival (OS) in PROpel: Abiraterone (abi) and olaparib (ola) vs abiraterone and placebo (pbo) as first-line (1L) therapy for metastatic castration-resistant prostate cancer (mCRPC). Presented at: 2023 American Society for Clinical Oncology Genitourinary Cancers Symposium; February 16-18, 2023. Abstract LBA16.
  8. Chi KN, Rathkopf DE, Raymond Smith M, et al. Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations. Presented at: 2022 American Society for Clinical Oncology Genitourinary Cancers Symposium; February 17-19, 2022. Abstract 12.
  9. Efstathiou E, Raymond Smith M, Sandhu S, et al. Niraparib (NIRA) with abiraterone acetate and prednisone (AAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Second interim analysis (IA2) of MAGNITUDE. Presented at: 2023 American Society for Clinical Oncology Genitourinary Cancers Symposium; February 16-18, 2023. Abstract 170.
  10. Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med2013;368:138-148.
  11. Kim JW, McKay RR, Radke MR, et al. Randomized trial of olaparib with or without cediranib for metastatic castration-resistant prostate cancer: The results from National Cancer Institute 9984. J Clin Oncol2023;41:871-880.
  12. Rucaparib [prescribing information]. Boulder, CO: Clovis Oncology, Inc; 2022.
  13. Bryce AH, Piulats JM, Reaume MN, et al. Rucaparib for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 interim overall survival and efficacy of rucaparib vs docetaxel or second-generation androgen pathway inhibitor therapy. Presented at: 2023 American Society for Clinical Oncology Genitourinary Cancers Symposium; February 16-18, 2023. Abstract 18.
  14. Fizazi K, Piulats JM, Reaume MN, et al. Rucaparib or physician's choice in metastatic prostate cancer. N Engl J Med2023;388:719-732.
  15. Fizazi K, Foulon S, Carles J, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 x 2 factorial design. Lancet2022;399:1695-1707.
  16. Smith MR, Hussain M, Saad F, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med2022;386:1132-1142.
  17. Hussain MHA, Tombal BF, Saad F, et al. Efficacy and safety of darolutamide (DARO) in combination with androgen-deprivation therapy (ADT) and docetaxel (DOC) by disease volume and disease risk in the phase 3 ARASENS study. Presented at: 2023 American Society for Clinical Oncology Genitourinary Cancers Symposium; February 16-18, 2023. Abstract 15.
  18. Hussain M, Tombal B, Saad F, et al. Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial. J Clin Oncol2023:JCO2300041.
  19. Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med2015;373:737-746.
  20. Fizazi K, Tran N, Fein L, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med2017;377:352-360.
  21. National Comprehensive Cancer Center. Clinical practice guidelines in oncology: Prostate cancer. Version 1.2023. nccn.org.
  22. van As NJ, Tree A, Ostler PJ, et al. PACE-A: An international phase 3 randomised controlled trial (RCT) comparing stereotactic body radiotherapy (SBRT) to surgery for localised prostate cancer (LPCa)—Primary endpoint analysis. Presented at: 2023 American Society for Clinical Oncology Genitourinary Cancers Symposium; February 16-18, 2023. Abstract 298.
  23. Jeong SH, Han JH, Jeong CW, et al. Clinical determinants of recurrence in pTa bladder cancer following transurethral resection of bladder tumor. BMC Cancer2022;22:631.
  24. Balar AV, Kamat AM, Kulkarni GS, et al. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol2021;22:919-930.
  25. Balar AV, Kamat AM, Kulkarni GS, et al. Pembrolizumab for the treatment of patients with high-risk (HR) non-muscle-invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guérin: Extended follow-up of KEYNOTE-057 cohort A. Presented at: 2021 American Society for Clinical Oncology Genitourinary Cancers Symposium; February 11-13, 2021. Abstract 451.
  26. Necchi A, Roumiguié M, Esen AA, et al. Pembrolizumab (pembro) monotherapy for patients (pts) with high-risk non–muscle-invasive bladder cancer (HR NMIBC) unresponsive to bacillus Calmette–Guérin (BCG): Results from cohort B of the phase 2 KEYNOTE-057 trial. Presented at: 2023 American Society for Clinical Oncology Genitourinary Cancers Symposium; February 16-18, 2023. Abstract LBA442.
  27. Patil G, Basu A. Emerging perioperative therapeutic approaches in muscle invasive bladder cancer. Ther Adv Urol2022;14:17562872221134389.
  28. Kaur J, Choi W, Geynisman DM, Plimack ER, Ghatalia P. Role of immunotherapy in localized muscle invasive urothelial cancer. Ther Adv Med Oncol2021;13:17588359211045858.
  29. Brown J, Kaimakliotis HZ, Kelly WK, et al. HCRN GU14-188: Phase Ib/II study of neoadjuvant pembrolizumab and chemotherapy for T2-4aN0M0 urothelial cancer. Presented at: 2023 American Society for Clinical Oncology Genitourinary Cancers Symposium; February 16-18, 2023. Abstract 448.
  30. Pfister C, Gravis G, Flechon A, et al. Randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin, or gemcitabine and cisplatin as perioperative chemotherapy for patients with muscle-invasive bladder cancer. Analysis of the GETUG/AFU V05 VESPER trial secondary endpoints: Chemotherapy toxicity and pathological responses. Eur Urol2021;79:214-221.
  31. Plimack ER, Hoffman-Censits JH, Viterbo R, et al. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. J Clin Oncol2014;32:1895-1901.
  32. Powles T, Kockx M, Rodriguez-Vida A, et al. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat Med2019;25:1706-1714.
  33. Powles T, Park SH, Voog E, et al. Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up results from the JAVELIN Bladder 100 trial. Presented at: 2022 American Society for Clinical Oncology Genitourinary Cancers Symposium; February 17-19, 2022. Abstract 487.
  34. Powles T, Park SH, Voog E, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med2020;383:1218-1230.
  35. Avelumab [prescribing information]. Darmstadt, Germany: Merck KGaA; 2022.
  36. Sridhar SS, Powles T, Gupta S, et al. Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up from the JAVELIN Bladder 100 trial in subgroups defined by 1L chemotherapy regimen and analysis of overall survival (OS) from start of 1L chemotherapy. Presented at: 2023 American Society for Clinical Oncology Genitourinary Cancers Symposium; February 16-18, 2023. Abstract 508.
  37. Tagawa ST, Balar AV, Petrylak DP, et al. Updated outcomes in TROPHY-U-01 cohort 1, a phase 2 study of sacituzumab govitecan (SG) in patients (pts) with metastatic urothelial cancer (mUC) that progressed after platinum (PT)-based chemotherapy and a checkpoint inhibitor (CPI). Presented at: 2023 American Society for Clinical Oncology Genitourinary Cancers Symposium; February 16-18, 2023. Abstract 526.
  38. Tagawa ST, Balar AV, Petrylak DP, et al. TROPHY-U-01: A phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. J Clin Oncol2021;39:2474-2485.
  39. Petrylak DP, Tagawa ST, Jain RK, et al. Primary analysis of TROPHY-U-01 cohort 2, a phase 2 study of sacituzumab govitecan (SG) in platinum (PT)-ineligible patients (pts) with metastatic urothelial cancer (mUC) that progressed after prior checkpoint inhibitor (CPI) therapy. Presented at: 2023 American Society for Clinical Oncology Genitourinary Cancers Symposium; February 16-18, 2023. Abstract 520.
  40. Enfortumab vedotin-ejfv [prescribing information]. Northbrook, Illinois: Astellas Pharma US, Inc; 223.
  41. Choueiri TK, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med2021;384:829-841.
  42. Motzer RJ, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. Lancet Oncol2022;23:888-898.
  43. Burotto M, Powles T, Escudier B, et al. Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3-year follow-up from the phase 3 CheckMate 9ER trial. Presented at: 2023 American Society for Clinical Oncology Genitourinary Cancers Symposium; February 16-18, 2023. Abstract 603.
  44. Albiges L, Schmidinger M, Taguieva-Pioger N, Perol D, Grunwald V, Guemas E. CaboPoint: a phase II study of cabozantinib as second-line treatment in patients with metastatic renal cell carcinoma. Future Oncol2022;18:915-926.
  45. Albiges L, Powles T, Sharma A, et al. CaboPoint: Interim results from a phase 2 study of cabozantinib after checkpoint inhibitor (CPI) therapy in patients with advanced renal cell carcinoma (RCC). Presented at: 2023 American Society for Clinical Oncology Genitourinary Cancers Symposium; February 16-18, 2023. Abstract 606.